ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Fischinger Hints of “New Player” At FCRF; Gigliotti Named Cancer Control Science Director

December 12, 1986

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996

NIH Programs: Mouse Is next In Line For DNA Sequencing

October 29, 1999

Drug Discovery Group Announcement Issued

January 7, 1983

Peter Shields Named Deputy Director At Ohio State

September 16, 2011

ASCO Names Stratetic Planning Committee

September 23, 1988